Momenta Pharmaceuticals, Inc. (MNTA)

[alternatepatel]

Spot On DD. But seems like MNTA won't get approval in 3Q at least.

Apart from that, MYL has been very confident that they "will be there at the market formation". That forces me to assume that there will be both MNTA and Mylan launching at the same time.

So that $240 mn is divided between 2 players = $120 mn for each

MNTA will share 50:50 with sandoz = $60 mn revenue /year. Doesn't look good at least in light of the long battle.